T2 Biosystems Announces Commercial Expansion Through Hong Kong And Macau Distributor; T2 Biosystems Will Sell The T2dD Instrument, The T2Bacteria Panel, The T2Candida Panel, And The T2Resistance Panel Through The Newly Appointed Distributor

6/25/24 9:16:17 AM ET

Medical/Dental Instruments

Health Care

Get the next $TTOO alert in real time by email

T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistant genes, today announced the execution of a territory exclusive distribution agreement in Hong Kong and Macau. Under the terms of the agreement, T2 Biosystems will sell the T2Dx® Instrument, the T2Bacteria® Panel, the T2Candida® Panel, and the T2Resistance® Panel through the newly appointed distributor.

Get the next $TTOO alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$TTOO

Date	Price Target	Rating	Analyst
2/18/2022	$0.70	Neutral → Buy	Alliance Global Partners

More analyst ratings

$TTOO
Financials

Live finance-specific insights

T2 Biosystems Announces Third Quarter 2024 Financial Results
LEXINGTON, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the "Company"), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced financial and operational results for the third quarter ended September 30, 2024. Recent Financial and Commercial Highlights Achieved third quarter total revenue of $2.0 million, representing an increase of 34% compared to the prior year period.Achieved sepsis test panel revenue of $1.4 million, representing an increase of 34% compared to the prior year period, driven by increased U.S. T2Bacteria® Panel revenue.Executed contracts for 11 T2Dx® Instruments during the third quar
11/14/24 4:05:00 PM ET
$TTOO
Medical/Dental Instruments
Health Care
T2 Biosystems to Report Third Quarter 2024 Financial Results and Business Updates on November 14, 2024
LEXINGTON, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it will report financial results for the third quarter 2024 and business updates after market close on Thursday, November 14, 2024. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.t2biosystems.com, on the Investors page in the Events & Presentations section. To listen to the conference call, please dial 877-545-0320
11/5/24 8:00:00 AM ET
$TTOO
Medical/Dental Instruments
Health Care
T2 Biosystems to Host Business Update Call on October 10, 2024
LEXINGTON, Mass., Oct. 08, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it will host a business update call to provide additional details on recent developments after market close at 4:30pm ET on Thursday October 10, 2024. On the call management also plans to address select questions from shareholders that can be submitted in advance to the investor relations team at [email protected]. Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.t2biosystems.com, on the Investors page in the
10/8/24 4:05:00 PM ET
$TTOO
Medical/Dental Instruments
Health Care

T2 Biosystems Announces Third Quarter 2024 Financial Results
LEXINGTON, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the "Company"), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced financial and operational results for the third quarter ended September 30, 2024. Recent Financial and Commercial Highlights Achieved third quarter total revenue of $2.0 million, representing an increase of 34% compared to the prior year period.Achieved sepsis test panel revenue of $1.4 million, representing an increase of 34% compared to the prior year period, driven by increased U.S. T2Bacteria® Panel revenue.Executed contracts for 11 T2Dx® Instruments during the third quar
11/14/24 4:05:00 PM ET
$TTOO
Medical/Dental Instruments
Health Care
T2 Biosystems to Report Third Quarter 2024 Financial Results and Business Updates on November 14, 2024
LEXINGTON, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it will report financial results for the third quarter 2024 and business updates after market close on Thursday, November 14, 2024. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.t2biosystems.com, on the Investors page in the Events & Presentations section. To listen to the conference call, please dial 877-545-0320
11/5/24 8:00:00 AM ET
$TTOO
Medical/Dental Instruments
Health Care
T2 Biosystems to Host Business Update Call on October 10, 2024
LEXINGTON, Mass., Oct. 08, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it will host a business update call to provide additional details on recent developments after market close at 4:30pm ET on Thursday October 10, 2024. On the call management also plans to address select questions from shareholders that can be submitted in advance to the investor relations team at [email protected]. Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.t2biosystems.com, on the Investors page in the
10/8/24 4:05:00 PM ET
$TTOO
Medical/Dental Instruments
Health Care

T2 Biosystems Announces Commercial Expansion Through Hong Kong And Macau Distributor; T2 Biosystems Will Sell The T2dD Instrument, The T2Bacteria Panel, The T2Candida Panel, And The T2Resistance Panel Through The Newly Appointed Distributor
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistant genes, today announced the execution of a territory exclusive distribution agreement in Hong Kong and Macau. Under the terms of the agreement, T2 Biosystems will sell the T2Dx® Instrument, the T2Bacteria® Panel, the T2Candida® Panel, and the T2Resistance® Panel through the newly appointed distributor.
6/25/24 9:16:17 AM ET
$TTOO
Medical/Dental Instruments
Health Care
T2 Biosystems Regains Compliance With Nasdaq
T2 Biosystems, Inc. (NASDAQ:TTOO) (the "Company"), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it received written notice from the Nasdaq Stock Market LLC ("Nasdaq") on May 21, 2024 informing the Company that it has regained compliance with the market value of listed securities ("MVLS") requirement, as set forth in Nasdaq Listing Rule 5550(b)(2) (the "Rule") for continued listing on the Nasdaq Capital Market.
5/22/24 9:13:50 AM ET
$TTOO
Medical/Dental Instruments
Health Care
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Lucy Scientific Discovery (NASDAQ:LSDI) shares moved upwards by 205.8% to $1.56 during Thursday's regular session. The company's market cap stands at $2.7 million. SINTX Techs (NASDAQ:SINT) shares moved upwards by 31.66% to $0.17. The company's market cap stands at $20.6 million. As per the news, the Q1 earnings report came out 3 days ago. Nanoviricides (AMEX:NNVC) stock increased by 23.56% to $2.22. The market value of their outstanding shares is at $26.1 million. The company's, Q3 earnings came out yesterday. Scorpius Holdings (AMEX:SCPX) shares moved upwards by 23.35% to $0.1. The company's market cap stands at $3.4 million. Onconetix (NASDAQ:ONCO) stock moved upwards by 23.2
5/16/24 12:31:11 PM ET
$ATNF
$BTCY
$ELTX
$EYEN
Biotechnology: Pharmaceutical Preparations
Health Care
Medical/Dental Instruments

$TTOO
Leadership Updates

Live Leadership Updates

Avacta Announces the Appointment of Darlene Deptula-Hicks as Non-Executive Director of the Board of Directors
Avacta Group plc Avacta Announces the Appointment of Darlene Deptula-Hicks as Non-Executive Director of the Board of Directors London, England; July 8, 2024; Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted cancer treatments and powerful diagnostics, today announced the appointment of Darlene Deptula-Hicks, MBA as a Non-Executive Director of the Company's Board of Directors, effective 26 June 2024. Ms. Deptula-Hicks is a highly accomplished financial executive with decades of experience working with and advising private and public life sciences companies. Shaun Chilton, Chairman of the Board of Avacta, commented: "Avacta is at a pivotal time in its e
7/8/24 8:15:00 AM ET
$PIRS
$TTOO
$FSTX
Biotechnology: Pharmaceutical Preparations
Health Care
Medical/Dental Instruments
T2 Biosystems Hires Industry Veteran Brett Giffin as Chief Commercial Officer
LEXINGTON, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced the appointment of Brett Giffin as its Chief Commercial Officer, effective November 8, 2021. As Chief Commercial Officer, Mr. Giffin will join the Company's executive leadership team and lead our commercial growth initiatives with direct responsibility for global sales, marketing, service, and customer support functions. Mr. Giffin replaces Anthony Pare, who recently accepted a role as CEO at BioPorto A/S. "We are thrilled to have Brett join T2 Biosystems as Chief Commercial Officer," said John Sperzel, Chairman and CEO at T2
11/4/21 4:04:00 PM ET
$TTOO
Medical/Dental Instruments
Health Care
T2 Biosystems Appoints Laura Adams to Its Board of Directors
LEXINGTON, Mass., Oct. 19, 2021 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced the appointment of Laura Adams to its Board of Directors, effective immediately. "We are excited to have Laura join the T2 Biosystems Board of Directors," said John Sperzel, Chairman and CEO at T2 Biosystems. "Her success as a healthcare delivery innovator has deep roots in understanding the critical threats posed by infections and sepsis. She will be a crucial asset to T2 Biosystems as we continue on our growth trajectory." Ms. Adams currently serves as Special Advisor at the National Academy of Medicine (NAM), providing lead
10/19/21 4:05:00 PM ET
$TTOO
Medical/Dental Instruments
Health Care

T2 Biosystems Announces Commercial Expansion Through Hong Kong And Macau Distributor; T2 Biosystems Will Sell The T2dD Instrument, The T2Bacteria Panel, The T2Candida Panel, And The T2Resistance Panel Through The Newly Appointed Distributor

Chat with this insight

Recent Analyst Ratings for $TTOO

$TTOO Financials

Live finance-specific insights

T2 Biosystems Announces Third Quarter 2024 Financial Results

T2 Biosystems to Report Third Quarter 2024 Financial Results and Business Updates on November 14, 2024

T2 Biosystems to Host Business Update Call on October 10, 2024

$TTOO Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G filed by T2 Biosystems Inc.

SEC Form SC 13G filed by T2 Biosystems Inc.

SEC Form SC 13G filed by T2 Biosystems Inc.

$TTOO Press Releases

Fastest customizable press release news feed in the world

T2 Biosystems Announces Third Quarter 2024 Financial Results

T2 Biosystems to Report Third Quarter 2024 Financial Results and Business Updates on November 14, 2024

T2 Biosystems to Host Business Update Call on October 10, 2024

$TTOO Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Elsbree David B sold $133 worth of shares (55 units at $2.42), decreasing direct ownership by 71% to 23 units (SEC Form 4)

Cr Group L.P. converted options into 1,824,800 shares (SEC Form 4)

Cr Group L.P. was granted 4,748,335 shares (SEC Form 4)

$TTOO SEC Filings

SEC Form DEF 14A filed by T2 Biosystems Inc.

T2 Biosystems Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

SEC Form 10-Q filed by T2 Biosystems Inc.

$TTOO Market Insights

Live Market Insights